Travere Therapeutics, Inc.

What they do

Travere develops and sells therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), holds full FDA approval in IgAN and, as of April 13, 2026, in FSGS. The company also runs a pivotal Phase 3 HARMONY Study of pegtibatinase in classical homocystinuria and in-licensed civorebrutinib to expand its rare kidney disease pipeline.

Revenue drivers

• FILSPARI in IgAN — The core commercial product, fully approved in September 2024 to slow kidney function decline in adults with primary IgAN. U.S. FILSPARI net product sales were $141.1 million in Q2 2026, up 96% year-over-year.
• FILSPARI in FSGS — FDA granted traditional approval on April 13, 2026, for proteinuria reduction in patients aged 8 and older with FSGS without nephrotic syndrome. The launch contributed to 2,012 new patient start forms in Q2 2026.
• Other commercial products — Total U.S. net product sales were $161.4 million in Q2 2026 and $285.8 million for the first half, so FILSPARI's $141.1 million was the large majority of reported product revenue.

Recent performance

Second quarter 2026 U.S. net product sales were $161.4 million versus $94.8 million a year earlier, with FILSPARI accounting for $141.1 million. Q2 2026 R&D expense was $60.3 million and SG&A was $96.1 million, both up year-over-year. Total other expense of $39.0 million included a $40.0 million inducement charge tied to 2029 convertible note repurchases. Net loss was $34.8 million, or $0.37 per basic share, versus $12.8 million a year earlier.

Strategy

Travere invests revenue from its commercial portfolio into its rare disease pipeline. Priorities include the FSGS launch, continued IgAN growth, and full enrollment of the Phase 3 HARMONY Study of pegtibatinase after enrollment was restarted in Q1 2026. The company also in-licensed civorebrutinib to broaden its immune-mediated rare kidney disease opportunities. Management states it will continue evaluating licenses and acquisitions in rare disease.

Risks

• Concentrated commercial dependence — The company states near-term revenue depends almost entirely on successful U.S. commercialization of FILSPARI in IgAN.
• Litigation and regulatory exposure — As a company with no prior-approved non-immunosuppressive IgAN treatment, FILSPARI's launch faces the risk of unsuccessful commercialization and payer or physician acceptance challenges.
• Pipeline timing risk — The pegtibatinase HARMONY Study was voluntarily paused in September 2024 and only restarted enrollment in Q1 2026 for manufacturing scale-up reasons.
• Thin equity and capital needs — At June 30, 2026, total liabilities of $774.8 million exceeded total assets of $799.4 million only modestly, leaving shareholder equity of $24.5 million and cash of $117.7 million.

Outlook

Management expects topline data from the pegtibatinase Phase 3 HARMONY Study in HCU in the second half of 2027. It describes the FSGS launch and IgAN growth as supporting near- and long-term growth, with continued investment in the commercial organization. The 8-K filings since the 10-K include two earnings releases and several agreements and officer changes, but no other specific guidance numbers were provided.